机构:[1]Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[2]Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming, China.[3]Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[4]Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China.
This work was funded by the National Natural
Science Foundation of China (Grant No. 81572288),
the Key Project of International Cooperation of
Science and Technology Innovation between
Governments, the National Key Research and
Development Plan of China (Grant No.
2016YEE0103400).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类|3 区医学
小类|3 区肿瘤学
最新[2023]版:
大类|3 区医学
小类|4 区肿瘤学
第一作者:
第一作者机构:[1]Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.[2]Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming, China.
共同第一作者:
通讯作者:
通讯机构:[1]Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.[3]Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.
推荐引用方式(GB/T 7714):
Chen Wenjie,Li Wen,Liu Zhenkun,et al.Identification of tumor microenvironment-based genes associated with acquired resistance to EGFR Tyrosine Kinase Inhibitor in Lung Adenocarcinoma.[J].Journal of Cancer.2022,13(3):877-889.doi:10.7150/jca.57008.
APA:
Chen Wenjie,Li Wen,Liu Zhenkun,Ma Guangzhi,Deng Yunfu...&Zhou Qinghua.(2022).Identification of tumor microenvironment-based genes associated with acquired resistance to EGFR Tyrosine Kinase Inhibitor in Lung Adenocarcinoma..Journal of Cancer,13,(3)
MLA:
Chen Wenjie,et al."Identification of tumor microenvironment-based genes associated with acquired resistance to EGFR Tyrosine Kinase Inhibitor in Lung Adenocarcinoma.".Journal of Cancer 13..3(2022):877-889